Records containing: Pancreatic Ductal Adenocarcinoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2025-07-08Identification of Predictive Plasma Biomarkers in Pancreatic Ductal Adenocarcinoma (PDAC Plasma Biomarker Study)
-
CLINICAL_TRIALS study record update · 2025-06-29Pilot Study of Mature Dendritic Cell Vaccination Against Mutated KRAS in Patients With Resectable Pancreatic Cancer
-
CLINICAL_TRIALS study record update · 2025-06-25FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
-
CLINICAL_TRIALS study record update · 2025-06-06A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating a Single Intravenous Push Followed by a Continuous Infusion of Certepetide Over 4 Hours When Added to Standard of Care (SoC) Versus Two Intravenous Pushes of Certepetide When Added to SoC, Versus SoC Alone in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (FORTIFIDE)
-
CLINICAL_TRIALS study record update · 2025-06-05Total Neoadjuvant NALIRIFOX Plus Ablative Dose Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-06-05An Open-label Phase 1 Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
-
CLINICAL_TRIALS study record update · 2025-06-05A Phase 1 Trial of Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma
-
CLINICAL_TRIALS study record update · 2025-06-03Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
-
CLINICAL_TRIALS study record update · 2025-05-21Pilot Study of Ketamine-assisted Talk Therapy for Demoralization in Advanced GI Cancer
-
CLINICAL_TRIALS study record update · 2025-05-20The WASH Trial: A Randomized Trial of Abdominal Lavage Using Distilled Water or Saline at High Volumes for Resected Pancreatic Cancer
-
CLINICAL_TRIALS study record update · 2025-05-02Generation of Patient Derived Pancreatic Cancer Cell Lines to Determine Mechanisms of Chemoresistance
-
CLINICAL_TRIALS study record update · 2025-04-29A Phase II Open-Label Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer and Good Performance Status
-
CLINICAL_TRIALS study record update · 2025-04-25A Retrospective/Prospective Study of an Artificial Intelligence Derived Histological Biomarker to Select Neoadjuvant Treatment for Patients With Borderline Resectable or Resectable Pancreatic Ductal Adenocarcinoma
-
CLINICAL_TRIALS study record update · 2025-04-24A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
-
CLINICAL_TRIALS study record update · 2025-04-16Window of Opportunity for Neoadjuvant Stroma Modification in Pancreatic Cancer
-
CLINICAL_TRIALS study record update · 2025-04-16A Phase II Open-Label Study of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma (EPIC)
-
CLINICAL_TRIALS study record update · 2025-03-19Artificial Intelligence-based Health Information Management System and Key Technology Study of Early Screening and Hierarchical Diagnosis and Treatment of Pancreatic Cancer
-
CLINICAL_TRIALS study record update · 2025-02-27A Phase 1b Dose-escalation and Cohort-expansion Study of the Safety/Tolerability, and Efficacy of Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer
-
CLINICAL_TRIALS study record update · 2025-02-07Advances in Imaging to Assess Response in Pancreatic Cancer (AIR-PANC): a Single Centre Feasibility Study
-
CLINICAL_TRIALS study record update · 2025-02-07Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
-
CLINICAL_TRIALS study record update · 2025-02-05A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination with Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients
-
CLINICAL_TRIALS study record update · 2025-01-31A Phase 1, Open-Label, Dose Escalation and Expansion Study of Mavrostobart (PT199) Administered Alone in Adult Patients with Advanced Solid TuMORs, in CombiNation with a Checkpoint INhibitor TreatinG Wild-type Non-Small Cell Lung Cancer, or in Combination with ChemoTherapy for Metastatic or Advanced PAncreatic Ductal AdenocaRcinoma (MORNINGSTAR)
-
CLINICAL_TRIALS study record update · 2025-01-28Multicenter Phase I/IIa Study of NASOX (Nal-IRI + S-1 + Oxaliplatin) as First-line Treatment for Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
-
CLINICAL_TRIALS study record update · 2025-01-17First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors
-
CLINICAL_TRIALS study record update · 2025-01-06A Multi-center, Open-label Phase II Study to Evaluate the Safety and Efficacy of YH003 in Combination with Toripalimab (anti-PD-1 MAb) in Patients with Unresectable/metastatic Melanoma and Pancreatic Ductal Adenocarcinoma (PDAC)